Pseudobulbar Affect TreatmentMarket Size, Share & Industry Analysis, By Treatment (Approved Therapies, Off Label Therapies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2024-2032

Pseudobulbar affect refers to an emotional disturbance condition, which is often characterized by episodes of sudden inappropriate and uncontrollable crying or laughing. Pseudobulbar affect is diagnosed in individuals with certain neurological illnesses or injuries, which makes it difficult for them to control their emotions and their exhibition. For instance, individuals with this disorder, experience emotions naturally but the way they show it is often exaggerated or considered inappropriate. Some of the individuals who are affected by this disorder can have preexisting neurological injuries or diseases like strokes, traumatic brain injury, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and Amyotrophic lateral sclerosis (ALS). The most primary symptom of the disease is the uncontrollable, frequent and involuntary fits of laughter and crying, with crying being the most common emotional display. One of the most distinguishing symptom of the disease also includes the length of each emotional response, which can last up to minutes and can be striking due to the contrast of the person’s emotional state, a little time ago. The treatment for the disease can be through a number of medications which also includes a range of antidepressants. For instance, a number of clinical trials have been conducted worldwide with the drug candidate AVP-923 (dextromethorphan/quinidine), a fixed-dose combination of two drugs, but no positive or significant clinical results have been achieved yet.

Global pseudobulbar affect treatment market growth is being driven by the increasing prevalence of pseudobulbar affect, increasing awareness regarding the disorder, rising demand for mental healthcare, increasing treatment options for pseudobulbar affect, increasing incidences of diagnosis due to advances in research, large proportions of unmet clinical needs and increasing research and development in the management of the disorder. According to the Brain Injury Association of America (BIAA), it is estimated that the symptoms of pseudobulbar affect affects 80% of the individuals who are suffering from brain injuries in the U.S. annually. These trends combined with the other factors are expected to positively drive the market growth.

In terms of limitations, the side effects associated with the treatment options and the lack of awareness regarding the disorder in the emerging markets that can restrain the growth in global pseudobulbar affect treatment market.

Key Players Covered:

The major companies covered in the global pseudobulbar affect treatment market report include Avanir Pharmaceuticals, Inc., Pfizer Inc., Eli Lilly and Company, Arrow Pharmaceuticals, ALLERGAN, and other players.

As per the current pseudobulbar affect treatment market trends, approved therapies among the treatment is anticipated to register a higher market share in the global pseudobulbar affect treatment market owing to improved efficacy offered by the therapy.

Key Insights:

• Prevalence Of Pseudobulbar Affect By Key Countries
• Advancements In Research & Of Treatment Options Development
• Overview Of Advances In Novel Therapeutics
• Pipeline Analysis
• New Product Launches
• Regulatory Scenario By Key Countries
• Key Industry Developments

Regional Analysis:

The global pseudobulbar affect treatment market has been segmented into North America, Europe, Asia Pacific, and the rest of world. North America dominates the global pseudobulbar affect treatment market due to a number of factors such as the increasing prevalence of pseudobulbar affect, increasing treatment options for pseudobulbar affect, established healthcare system, high healthcare expenditure, access to advanced diagnostics regarding brain injuries leading to greater diagnosis of cases, increasing investment in treatment options and rising demand for preventive medical care.

Europe is estimated to be the second-largest market because of the increased adoption of advanced therapeutics for the disorder. Asia Pacific is the fastest emerging market due to increasing awareness of pseudobulbar affect treatment, increasing access to advanced treatment options, large population bases, increasing disposable incomes, increasing awareness and demand for advanced diagnostic procedures and developing healthcare systems. Additionally, pseudobulbar affect treatment market in rest of world is in the nascent stage; however, unmet needs for mental disorders is expected to drive the market growth in this region.

Segmentation

Pseudobulbar Affect Treatment Industry Developments

• In December 2019, Avanir Pharmaceuticals, Inc. announced that the clinical trials for AVP-786 for the possible treatment of agitation in Alzheimer’s Patients, a drug designed to be second generation version of Nuedexta, a drug approved for pseudobulbar affect treatment, will continue.
• In August 2019, SHINKEI Therapeutics announced the submission of Investigational New Drug Application Submission for MR-201, a novel therapeutic for the treatment of pseudobulbar affect.